...
search icon
igms-img

IGM Biosciences Inc, Common Stock

IGMS

NSQ

$1.47

-$0.11

(-6.96%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$87.41M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
407.49K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.19
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.55 L
$22.5 H
$1.47

About IGM Biosciences Inc, Common Stock

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameIGMSSectorS&P500
1-Week Return-13.53%3.05%-0.32%
1-Month Return-75.7%6.76%2.75%
3-Month Return-91.48%-1.27%3.94%
6-Month Return-87.07%-2.35%11.01%
1-Year Return-86.31%4.47%23.11%
3-Year Return-91.69%11.65%34.36%
5-Year Return-96.01%43.79%85.19%
10-Year Return-93.95%108.21%200.02%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue--366.00K1.07M2.13M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":17.18,"profit":true},{"date":"2022-12-31","value":50.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue22.65M3.58M7.72M10.60M8.28M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":15.79,"profit":true},{"date":"2021-12-31","value":34.1,"profit":true},{"date":"2022-12-31","value":46.81,"profit":true},{"date":"2023-12-31","value":36.54,"profit":true}]
Gross Profit(22.65M)(3.58M)(7.72M)1.07M(6.15M)[{"date":"2019-12-31","value":-2118.71,"profit":false},{"date":"2020-12-31","value":-334.52,"profit":false},{"date":"2021-12-31","value":-722.54,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-575.02,"profit":false}]
Gross Margin(Infinity%)(Infinity%)(2110.38%)100.00%(288.59%)[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":-2110.38,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-288.59,"profit":false}]
Operating Expenses44.50M83.28M165.32M229.03M265.59M[{"date":"2019-12-31","value":16.75,"profit":true},{"date":"2020-12-31","value":31.36,"profit":true},{"date":"2021-12-31","value":62.25,"profit":true},{"date":"2022-12-31","value":86.23,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(44.50M)(83.28M)(165.32M)(227.96M)(263.46M)[{"date":"2019-12-31","value":-4449800000,"profit":false},{"date":"2020-12-31","value":-8328000000,"profit":false},{"date":"2021-12-31","value":-16532300000,"profit":false},{"date":"2022-12-31","value":-22795600000,"profit":false},{"date":"2023-12-31","value":-26346100000,"profit":false}]
Total Non-Operating Income/Expense-3.85M318.00K13.89M34.55M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":11.14,"profit":true},{"date":"2021-12-31","value":0.92,"profit":true},{"date":"2022-12-31","value":40.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(43.13M)(81.36M)(165.16M)(221.10M)(245.74M)[{"date":"2019-12-31","value":-4313300000,"profit":false},{"date":"2020-12-31","value":-8135500000,"profit":false},{"date":"2021-12-31","value":-16516400000,"profit":false},{"date":"2022-12-31","value":-22110200000,"profit":false},{"date":"2023-12-31","value":-24573800000,"profit":false}]
Income Taxes(597.00K)(1.02M)(4.48M)(6.85M)678.00K[{"date":"2019-12-31","value":-88.05,"profit":false},{"date":"2020-12-31","value":-151.18,"profit":false},{"date":"2021-12-31","value":-661.36,"profit":false},{"date":"2022-12-31","value":-1010.91,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes-(80.33M)(160.68M)(214.25M)(246.42M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-8033000000,"profit":false},{"date":"2021-12-31","value":-16068000000,"profit":false},{"date":"2022-12-31","value":-21424800000,"profit":false},{"date":"2023-12-31","value":-24641600000,"profit":false}]
Income From Continuous Operations(43.13M)(81.36M)(165.16M)(221.10M)(238.30M)[{"date":"2019-12-31","value":-4313300000,"profit":false},{"date":"2020-12-31","value":-8135500000,"profit":false},{"date":"2021-12-31","value":-16516400000,"profit":false},{"date":"2022-12-31","value":-22110200000,"profit":false},{"date":"2023-12-31","value":-23829700000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(42.54M)(80.33M)(160.68M)(214.25M)(246.42M)[{"date":"2019-12-31","value":-4253600000,"profit":false},{"date":"2020-12-31","value":-8033000000,"profit":false},{"date":"2021-12-31","value":-16068000000,"profit":false},{"date":"2022-12-31","value":-21424800000,"profit":false},{"date":"2023-12-31","value":-24641600000,"profit":false}]
EPS (Diluted)(5.59)(2.65)(4.93)(5.37)(4.81)[{"date":"2019-12-31","value":-559,"profit":false},{"date":"2020-12-31","value":-265,"profit":false},{"date":"2021-12-31","value":-493,"profit":false},{"date":"2022-12-31","value":-537,"profit":false},{"date":"2023-12-31","value":-481,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

IGMS
Cash Ratio 4.98
Current Ratio 5.22

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

IGMS
ROA (LTM) -37.38%
ROE (LTM) -132.11%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

IGMS
Debt Ratio Lower is generally better. Negative is bad. 0.74
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.26

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

IGMS
Trailing PE NM
Forward PE NM
P/S (TTM) 32.20
P/B 1.25
Price/FCF NM
EV/R 277.37
EV/Ebitda NM

FAQs

What is IGM Biosciences Inc share price today?

IGM Biosciences Inc (IGMS) share price today is $1.47

Can Indians buy IGM Biosciences Inc shares?

Yes, Indians can buy shares of IGM Biosciences Inc (IGMS) on Vested. To buy IGM Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IGMS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of IGM Biosciences Inc be purchased?

Yes, you can purchase fractional shares of IGM Biosciences Inc (IGMS) via the Vested app. You can start investing in IGM Biosciences Inc (IGMS) with a minimum investment of $1.

How to invest in IGM Biosciences Inc shares from India?

You can invest in shares of IGM Biosciences Inc (IGMS) via Vested in three simple steps:

  • Click on Sign Up or Invest in IGMS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in IGM Biosciences Inc shares
What is IGM Biosciences Inc 52-week high and low stock price?

The 52-week high price of IGM Biosciences Inc (IGMS) is $22.5. The 52-week low price of IGM Biosciences Inc (IGMS) is $1.55.

What is IGM Biosciences Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of IGM Biosciences Inc (IGMS) is 1.25

What is the Market Cap of IGM Biosciences Inc?

The market capitalization of IGM Biosciences Inc (IGMS) is $87.41M

What is IGM Biosciences Inc’s stock symbol?

The stock symbol (or ticker) of IGM Biosciences Inc is IGMS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top